Jazz Pharmaceuticals EVP & CMO Sells $19.2M in Pre-Arranged 10b5-1 Plan
Jazz Pharmaceuticals plc
Subscribe to track JAZZ
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
š Form 4 Filing Summary for Jazz Pharmaceuticals plc ($JAZZ)
Insider: Robert Iannone (EVP, Global Head of R&D & CMO) Transaction Date: August 27, 2026 Filing Date: August 31, 2026
Transaction Overview: ā¢ Action: Stock Option Exercise & Sale (Rule 10b5-1) ā¢ Options Exercised: 57,500 shares ($113.10 - $137.12) ā¢ Shares Sold: 76,921 ordinary shares ā¢ Average Sale Price: ~$249.70 (prices ranging $247.29 - $252.76) ā¢ Total Sale Proceeds: ~$19,207,098 ā¢ Post-Transaction Holdings: 65,686 shares
Note: Transactions were executed automatically under a pre-established Rule 10b5-1 trading plan adopted on May 28, 2026.
Comprehensive Analysis
Executive Summary
On August 31, 2026, Jazz Pharmaceuticals plc ($JAZZ) filed a Form 4 disclosing transactions by Dr. Robert Iannone, Executive Vice President, Global Head of R&D and Chief Medical Officer. On August 27, 2026, Dr. Iannone exercised stock options for 57,500 shares and sold a total of 76,921 ordinary shares for gross proceeds of approximately $19.21 million at weighted average prices ranging from $247.86 to $252.76 per share.
Transaction Details
- Option Exercises:
- 27,000 shares exercised at $113.10 per share (26,116 Non-Qualified Stock Options, 884 Incentive Stock Options).
- 30,500 shares exercised at $137.12 per share (27,584 Non-Qualified Stock Options, 2,916 Incentive Stock Options).
- Open Market Sales:
- 18,187 shares at a weighted average price of $247.8573
- 11,423 shares at a weighted average price of $248.6664
- 18,113 shares at a weighted average price of $250.0178
- 19,639 shares at a weighted average price of $250.6032
- 9,259 shares at a weighted average price of $251.9499
- 300 shares at $252.76
- Net Impact: Following these transactions, Dr. Iannone directly holds 65,686 ordinary shares of Jazz Pharmaceuticals.
Trading Significance
The trading significance is assessed as Low because all transactions were executed automatically under a Rule 10b5-1 trading plan established on May 28, 2026. Such scheduled option exercises and systematic dispositions are standard executive compensation management and do not reflect discretionary timing or directional sentiment on the company's near-term outlook.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is AI-generated from public SEC filings and may contain errors. It is for informational and educational purposes only and is not investment, legal, or tax advice.
The Filing Fool is not a registered investment adviser, broker-dealer, or financial planner. Nothing here is a recommendation or solicitation to buy, sell, or hold any security.
Always do your own due diligence and consult a licensed professional.